Sodium Fructose Diphosphate Injection
Function and Efficacy
This product is an intermediate product of sugar metabolism in the body. It produces pharmacological effects by regulating the activity of several enzymes in sugar metabolism. Exogenous 1,6-diphosphate fructose can increase the concentration of intracellular adenosine triphosphate and creatine phosphate, promote the influx of potassium ions, increase the content of diphosphoglycerate in red blood cells, inhibit the release of oxygen free radicals and histamine, and other pharmacological effects. It can reduce the damage caused by ischemia and hypoxia, especially for ischemic heart disease. Acute toxicity tests show that the lethal dose of experimental mice and experimental rabbits is 5.0g/kg and 5.8g/kg respectively when FDP is intravenously infused at a rate of 0.4 and 0.6g/kg/min. Acute toxicity seems to be related to the toxicity caused by the large amount of inorganic phosphorus entering the systemic circulation after the hydrolysis of large doses of FDP.
Ingredients
Sodium fructose diphosphate. Molecular formula: C6H11O12P2Na3 Molecular weight: 406.06
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| D-fructose 1,6-bis(dihydrogen phosphate)Ingredients |
This product is an intermediate product of sugar metabolism in the body. It produces pharmacological effects by regulating the activity of several enzymes in sugar metabolism. Exogenous 1,6-diphosphate fructose can increase the concentration of adenosine triphosphate and creatine phosphate in cells, promote the influx of potassium ions, increase the content of diphosphoglycerate in red blood cells, inhibit the release of oxygen free radicals and histamine, and has many other pharmacological effects. It can reduce the damage caused by ischemia and hypoxia, especially for ischemic heart disease. More |
488-69-7 | 9 |
Appearance
This product is a colorless or almost colorless clear liquid.
Indication
It is suitable for improving angina pectoris of coronary heart disease, acute myocardial infarction and arrhythmia, and myocardial ischemia of heart failure.
Usage and Dosage
Intravenous drip, 50-100 ml each time, 1-2 times a day, maximum amount 200 ml/day, intravenous drip rate 4-7 ml per minute, or as directed by the doctor. In case of heart failure, the dose can be halved.
Adverse Reactions
Pain at the infusion site, rash, numbness of the lips, and occasionally dizziness, chest tightness and allergic reactions.
Precautions
It is contraindicated for patients who are allergic to this product, have hyperphosphatemia, or renal failure.
Drug Interactions
This product should be used alone and should not be dissolved in other drugs.
Storage
Keep tightly closed in a cool place.
Packaging Specification
100ml:10g (calculated as anhydrous)
Validity Period
24 months
Manufacturer
Beijing Huajin Pharmaceutical Co., Ltd.
-
Founded in:
1992-07-20 -
Address:
No. 01, 1st to 3rd Floor, Building 3, No. 31 Xinggu Road, Xinggu Street, Pinggu District, Beijing -
Tax NO.:
91110105600024567L -
Registered Funds:
7.8864 million yuan -
Website:
-
Email: